Sonrotoclax, Zanubrutinib, and CD20 Antibody for Untreated Mantle Cell Lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs—sonrotoclax, zanubrutinib, and a CD20 antibody—as a first treatment for mantle cell lymphoma. It aims to see if this new combination is safe and effective for patients who have not yet received any treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with mantle cell lymphoma (MCL) and have not had any previous treatment for it.
- You are able to care for yourself (ECOG performance status of 2 or less).
- You have adequate bone marrow, kidney, and liver function as shown by blood tests.
- You do not have untreated hepatitis B or C, or HIV infection.
- You have not had a prior stem cell transplant, CAR-T therapy, or treatment with a BCL2 or BTK inhibitor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—obinutuzumab, zanubrutinib, and lenalidomide—as a first treatment for mantle cell lymphoma. The goal is to see if this approach is safe and effective for patients who have not had prior therapy.
This trial tests a combination of three drugs (pomalidomide, orelabrutinib, and zuberitamab) in people with Mantle Cell Lymphoma who have not yet received treatment. It aims to see if this combination works better than standard therapy, especially for those with high-risk features.
This trial tests a new combination of three targeted therapies for people newly diagnosed with a high-risk form of mantle cell lymphoma (MCL), a rare blood cancer. The goal is to see if this combination is safe and effective in shrinking or eliminating the cancer.
This trial tests a new combination of two targeted therapies for people with mantle cell lymphoma that has come back or hasn't responded to prior treatment. It aims to see if adding sonrotoclax to zanubrutinib works better than zanubrutinib alone.
This trial tests a combination of three medications (zanubrutinib, obinutuzumab, and sonrotoclax) for people with mantle cell lymphoma, a type of blood cancer. The goal is to see if this combination is safe and effective, and it may be an option for people who are older or have health issues that make a stem cell transplant too risky.
This study tests a combination of a targeted pill (zanubrutinib) with standard chemotherapy (R-CHOP/R-DHAP) for people newly diagnosed with mantle cell lymphoma. The goal is to see how well this approach works and to potentially improve treatment outcomes for this type of lymphoma.
Hear when a new MCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.